Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Characteristics of Treatment Responders to Galantamine

This study has been completed.
Sponsor:
Collaborator:
Janssen Korea, Ltd., Korea
Information provided by (Responsible Party):
Doh Kwan Kim, Samsung Medical Center
ClinicalTrials.gov Identifier:
NCT01029132
First received: December 6, 2009
Last updated: January 4, 2016
Last verified: January 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: October 2009
  Primary Completion Date: October 2009 (Final data collection date for primary outcome measure)